Atrial fibrillation recurred in only 4.5% of the patients in the vitamin C group, as compared with 36.3% of the patients who did not receive any treatment (Korantzopoulos 2005)
It is crucial to promptly explore innovative approaches to tackle MASLD
Cascone T, Leung CH, Weisferdt A, Pataer A, Carter BW, Godoy MCB, Feldman H, Jr WW, Xi Y, Basu S, Sun JJ, Yadav SS, Rojas Alvarez FR, Lee Y, Mishra AK, Chen L Pradhan M, Guo H, Sinjab A, Zhou N, Negrao MV, Le X, Gay CM, Tsao AS, Byers LA, Altan M, Glisson BS, Fossella FV, Elamin YY, Jr BG, Zhang J, Skoulidis F, Wu J, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL , Rajaram R, Antonoff MB, Fujimoto J, Solis LM, Parra ER, Haymaker C, Wistuba II, Swisher SG, Vaporciyan AA, Hy L, Wang J, Gibbons DL, Jack Lee J, Ajami NJ, Wargo JA, Allison JP, Sharma P, Kadara H, Heymach JV, Sepesi B
Interpatient variability in bioavailability is related to the extent of absorption: implications for bioavailability and bioequivalence studies
